Shares of Natco Pharma rallied 9 per cent to Rs 920 on the BSE in Tuesday’s intra-day trade after the company launched its first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the US market. Natco, along with marketing partner Teva, has launched these strengths of lenalidomide.

• Developers Race to Remove Anthropic’s Invisible AI Watermarks
• Godrej Industries Plans Rs 20,000 Crore Investment in Haryana
• Asaya Raises Rs 88 Crore, Plans Offline Retail Expansion
• NTPC Green Energy Arm Wins 500 MW SECI Peak Power Tender
• Natco Pharma Facility Gets 4 USFDA Observations; Shares Up 

In the above strengths of lenalidomide, capsules are prescribed in adults to treat multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment, Natco Pharma said in an exchange filing.